Biologics referral form

Phone:		
Fax:		

PATIENT INFORMATION					
Acute care specialist name: Phone				Phone:	
Patient: see attached Gen	der: Male	Female			
Patient name:			DOB:	SSN:	
Address:				City:	
State:		ZIP:	Phone:	Cell:	
Emergency contact:			Phone:	Relationship:	
Insurance: Front and back of	of insurance card to	ofollow			
Primary Insurance:		Phone:	Policy #:	Group:	
Secondary Insurance:		Phone:	Policy #:	Group:	
Primary diagnosis:			Diagnosis:		
Medical assessment: Height:_	Weig	ht: lbs [kg		
Current medications? Yes	No		If yes, list or attach:		
Allergies:					
TB test: most recent date:		see attached for results and	details No TB test in past	year	
Tried & failed therapies: Include	de supportive clinic	cal documents			
Azathioprine Corticoster	oids Enbrel	☐ Humira ☐ Methotrexat	e NSAIDS		
5-Aminosalicyclic Acid Agent	s 6-mercaptor	ourine			
Other:					
DDECCRIPTION AND ORE	SEDC M. P. d'	· (
PRESCRIPTION AND ORE Medication	Dose & Directi		led rate and via rate controlle	d device per therapy	
Entyvio,			han navt dasa is naadad.		
x1 year	First Dose: No If NO, indicate when next dose is needed: Induction Dose: Week 2, Date Due: Week 6, Date Due:				
	Maintenance [Oose: Date Due:			
		ose: Infuse 300mg IV at we			
Stelara,	☐ Maintenance Dose: Infuse 300mg IV every 8 weeks First Dose: ☐ Yes ☐ No If NO, indicate when next SC dose is needed: Date Due:				
x1 year		Induction Dose:	Herritext se dose is needed. B	ate bae	
			mg (2 x130mg/26mL vials) IV a		
	Patients weighing > 55 kg to 85 kg: Infuse 390 mg (3 x 130mg/26mL vials) IV at week 0 Patients weighing > 85 kg: Infuse 520 mg (4 x 130mg/26mL vials) IV at week 0				
		nance Dose: Inject 90mg SC	5	at week o	
Infliximab (Remicade;	Remicade	Inflectra Renflexis	Avsola		
Inflectra; Renflexis; Avsola), x1 year	ectra; Renflexis; Avsola), First Dose: Yes No Indicate when next dose is needed if still in induction phase:				
XI you			Week 6, Date Due:		
	Maintenance Dose: Date Due: Induction Dose: Infuse 5mg/kg ormg/kg IV at weeks 0, 2 and 6				
	Maintenance Dose: Infusemg/kg IV every 8 weeks				
		mg/kg IV every		22	
	irirusion time: Infi	use overnours if d	ifferent than PI recommendation		

Biologics referral form

	Phone:
	Fax:
	rax
Patient name:	DOB:

PRESCRIPTION AND	ORDERS Medication infused per PI r	ecommended rate and via rate	controlled device	per therapy		
Medication	Dose & Directions					
Pre-Medications, x1 year	Administer 30 minutes prior to infusion Acetaminophen 325mg PO 650mg POmg PO DiphenhydrAMINE 25mg PO 50mg POmg PO Other					
Lab Orders, x1 year	Albumin ALT AST CBC Creatinine CMP CRP ESR LFT Platelets Other Frequency of labs:					
Nursing Orders, x1 year	Nursing to administer prescribed medication and establish and/or maintain IV access device. IV access to be flushed by nurse: Sodium Chloride 0.9%: 5mLs pre-infusion and 5mLs post infusion If Entyvio: Sodium Chloride 0.9% 5mLs pre infusion and 30mLs post infusion If Port access: Sodium Chloride 0.9%, 10mls pre-infusion and 10mLs post-infusion followed by Heparin 100 units/mL, 5mLs as final lock for patency					
Pharmacy Orders, x1 year	Pharmacy to dispense flushes, needles, syringes and HME/DME quantity sufficient to complete therapy as prescribed.					
X Anaphylaxis kit order	Infusion Reaction Management x1 year					
Mild	• Slow infusion rate by 50% until symptoms resolve. Resume at previous rate as tolerated. X DiphenhydrAMINE PO 25mg 50mgmg Dispense diphenhydrAMINE 25mg capsules x 4					
Moderate	• Stop Infusion, resume at 50% rate when symptoms resolve DiphenhydrAMINE IV 25mg 50mg mg Dispense diphenhydrAMINE 50mg vial x 1					
Severe (Anaphylaxis) *Call 911* Notify prescribing physician	 Stop infusion and remove tubing from access device to prevent further administration Initiate 0.9% NaCl 500mL/hr IV OR mL/hr Administer EPINEPHrine 1mg/mL by weight (Wt.) as an IM injection into the lateral thigh					
PHYSICIAN INFORMA	ATION					
Name:		Practice:				
Address:		City:	State:	ZIP:		
Phone:	Fax:	NPI:	Contact:			
By signing, I certify/recertify that the above therapy, products and services are medically necessary and that this patient is under my care. I have received authorization to release the above referenced information and medical and/or patient information relating to this therapy. Pharmacy has my permission to contact the insurance company on my behalf to obtain authorization for patient.						
Please fax: Completed form Demographic sheet/insurance information Clinical notes and lab TB results						
Signature:	Signature: Date:					